1,5,9-Triazaanthracen | 68671-74-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1,5,9-Triazaanthracen
• 英文别名: pyrido[2,3-b][1,5]naphthyridine；Pyridonaphthyridine；pyrido[2,3-b][1,5]naphthyridine
• CAS: 68671-74-9
• 化学式: C₁₁H₇N₃
• 分子量: 181.197
• InChiKey: JZKJGYBMTGSLJH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  9,10-Dihydro-1,5,9-triazaanthracen 以48%的产率得到
  参考文献：
  名称：

  CZUBA W.; BAJGROWICZ J. A., POL. J. CHEM., 1978, 52, NO 7-8, 1395-1402

  摘要：

  DOI：

文献信息

• Pyridonaphthyridine PI3K/MTOR Dual Inhibitors and Preparation and Use Thereof
  申请人：Wu Frank

  公开号：US20140093505A1

  公开（公告）日：2014-04-03

  The present invention relates to a pyridonaphthyridine compound as represented by general formula (I), which has a dual PI3K and mTOR inhibition effect, and its pharmaceutically acceptable salt, stereoisomer and deuteride thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and X are as defined in the specification; the present invention also relates to a method for preparing said compound, a pharmaceutical composition and a pharmaceutical formulation containing said compound, and uses of said compound in treating and/or preventing a proliferative disease and in the manufacture of a medicament for treating and/or preventing a proliferative disease.

  本发明涉及一种由通式（I）表示的吡啶萘啉化合物，其具有双重PI3K和mTOR抑制作用，以及其药学上可接受的盐、立体异构体和氘代物，其中R1、R2、R3、R4、R5、R6、R7和X如规范中所定义；本发明还涉及一种制备所述化合物的方法，含有所述化合物的药物组合物和药物配方，以及所述化合物在治疗和/或预防增殖性疾病以及制造用于治疗和/或预防增殖性疾病的药物的用途。
• NITRILES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1724264A1

  公开（公告）日：2006-11-22

  The present invention relates to a compound of formula (I) wherein Y and Z each is independently N or C; ring A is a carbocyclic group or a heterocyclic group; ring B is a heterocyclic group containing at least one nitrogen atom; R is a hydrogen atom, a substituent, etc,; n is 0, or an integer of from 1 to 10, a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof. The compound of formula (I), a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof has an inhibitory activity against cysteine protease, and it is useful for the prophylaxis and/or treatment of a cysteine protease-related disease such as osteoporosis, etc.

  本发明涉及一种具有以下式（I）的化合物，其中Y和Z各自独立地为N或C；环A为碳环基团或杂环基团；环B为含有至少一个氮原子的杂环基团；R为氢原子、取代基等；n为0，或为1至10的整数，其盐、溶剂合物、N-氧化物或前药。具有式（I）的化合物，其盐、溶剂合物、N-氧化物或前药对半胱氨酸蛋白酶具有抑制活性，对于预防和/或治疗半胱氨酸蛋白酶相关疾病如骨质疏松症等是有用的。
• Reactive Azo Dyes, Methods for the Production Thereof and Their Use
  申请人：Gorlitz Gunter

  公开号：US20080289124A1

  公开（公告）日：2008-11-27

  Reactive dyes of the formula (1) where R 1 to R 5 , Ar, n, Y and D are as defined in claims 1 and 2 are described, as are processes for preparing them, and their use for dyeing and printing carboxamido-, amino-, and hydroxyl-containing material.

  描述了化学式（1）中的活性染料，其中R1至R5，Ar，n，Y和D的定义如权利要求1和2中所述，还描述了制备这些染料的方法，以及它们在染色和印花含有羧胺基，氨基和羟基的材料中的应用。
• Novel tricyclic heterocycle compound
  申请人：Ohmoto Kazuyuki

  公开号：US20060154944A1

  公开（公告）日：2006-07-13

  The present invention relates to the compound represented by formula (I) A—X—Y-Z-B  (I) (wherein A is a cyclic group which may have a substituent(s); X is a single bond or a spacer; Y is a single bond or a spacer; Z is a single bond or a spacer; B is a hydrocarbon group which may have a substituent(s) or a cyclic group which may have a substituent(s)), a salt thereof, a solvate thereof or a prodrug thereof. The compound represented by formula (I), a salt thereof, a solvate thereof or a prodrug thereof is useful for preventive and/or therapeutic agent for a disease caused by stress.

  本发明涉及由式(I)A—X—Y-Z-B所表示的化合物（其中A是可能具有取代基的环状基团；X是单键或间隔物；Y是单键或间隔物；Z是单键或间隔物；B是可能具有取代基的碳氢基团或环状基团），其盐、溶剂化物或前药。该式(I)化合物、其盐、溶剂化物或前药可用作预防和/或治疗由压力引起的疾病的药物。
• PROTEOMIMETIC COMPOUNDS AS INHIBITORS OF THE INTERACTION OF NUCLEAR RECEPTOR WITH COACTIVATOR PEPTIDES
  申请人：Hamilton Andrew

  公开号：US20090220586A1

  公开（公告）日：2009-09-03

  The present invention relates to compounds, pharmaceutical compositions and methods which inhibit the binding of coactivator proteins in nuclear receptors, including estrogen receptors (alpha and/or beta), androgen receptors, thyroid receptors and peroxisome proliferators-activated receptors, among others. Compounds according to the present invention may be useful in the treatment of a variety of disease states or conditions which are mediated through nuclear receptors.

  本发明涉及抑制核受体中的共激活蛋白结合的化合物、药物组合物和方法，包括雌激素受体（α和/或β）、雄激素受体、甲状腺受体和过氧化物酶体增殖物激活受体等。根据本发明的化合物可能在治疗通过核受体介导的各种疾病状态或病情中有用。